Quarterly report · Q2
2385.TEDINET S100Q4ZE
Period2022-07-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.2bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥9.3bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.2bn | 2021-07-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥584m | 2021-07-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥629m | 2021-07-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥345m | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥628m | 2021-07-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥209m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥810m | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥415m | 2021-07-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥421m | 2021-07-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥8.0bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥8.1bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.0bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥1.6bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥6.9bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.8bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥6.5bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.5bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.0bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.0bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2021-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥328m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥27m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥245m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥23m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥130m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥130m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥129m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥8 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.47 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.95 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.86 | 2021-07-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.71 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 84.4% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥2m |
| Reconciling Itemsreconciling | revenue external | 2022-07-01 → 2022-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | −¥155m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥258m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥258m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥32m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥398m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2022-07-01 → 2022-12-31 | −¥18m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥279m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥277m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥314m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥314m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥45m |
| —segment total | revenue | 2022-07-01 → 2022-12-31 | ¥4.2bn |
| —segment total | revenue external | 2022-07-01 → 2022-12-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥3m |
| —segment total | segment profit | 2022-07-01 → 2022-12-31 | ¥500m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-12-31 | −¥2m |
| Reconciling Itemsreconciling | revenue external | 2021-07-01 → 2021-12-31 | ¥900,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-12-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-12-31 | −¥162m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥231m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥231m |
| jpcrp040300-q2r_E05367-000Clinical Evidence Servicereportable segment | segment profit | 2021-07-01 → 2021-12-31 | −¥6m |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥2.7bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥2.7bn |
| jpcrp040300-q2r_E05367-000Functional Cosmetic Retailingreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥659m |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥1.6bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥1.6bn |
| jpcrp040300-q2r_E05367-000Functional Food Retailingreportable segment | segment profit | 2021-07-01 → 2021-12-31 | −¥22m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥360m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥358m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥3m |
| jpcrp040300-q2r_E05367-000Functional Material Developmentreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥63m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥315m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥315m |
| jpcrp040300-q2r_E05367-000Health Care Support Servicereportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥52m |
| —segment total | revenue | 2021-07-01 → 2021-12-31 | ¥5.2bn |
| —segment total | revenue external | 2021-07-01 → 2021-12-31 | ¥5.1bn |
| —segment total | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥3m |
| —segment total | segment profit | 2021-07-01 → 2021-12-31 | ¥746m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 442
| Item | Context | Value | Unit |
|---|---|---|---|
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 63124000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 745880000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -161621000 | JPY |
| Operating income | Prior1YTDDuration | 584259000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 258436000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 314241000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 1960299000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1413450000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 276511000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 4222939000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | 900000 | JPY |
| Revenues from external customers | CurrentYTDDuration | 4223839000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 2547000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 2547000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -2547000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 258436000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 314241000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 1960299000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | 1413450000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 279058000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 4225486000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -1647000 | JPY |
| Net sales | CurrentYTDDuration | 4223839000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000ClinicalEvidenceServiceReportableSegmentsMember | 31518000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000HealthCareSupportServiceReportableSegmentsMember | 45490000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember | 398195000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalFoodRetailingReportableSegmentsMember | -17884000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember | 42700000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 500018000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -155494000 | JPY |
| Operating income | CurrentYTDDuration | 344523000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-02-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第29期第２四半期（自 2022年10月１日 至 2022年12月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社総医研ホールディングス | |
| Company name in english cover page | FilingDateInstant | Soiken Holdings Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 石神 賢太郎 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府豊中市新千里東町一丁目４番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06（6871）8888 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役財務部長 十河 健一 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪府豊中市新千里東町一丁目４番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06（6871）8888 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役財務部長 十河 健一 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |